OIPE JC10
JUL 05 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/679,036
Filing Date	10-02-2003
First Named Inventor	MIKSZTA et al.
Art Unit	1648
Examiner Name	MICHAEL M. MCGAW
Attorney Docket Number	P-6088

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AD		US- 2004131641	07-08-2004	MIKSZTA et al.	
AD		US- 2004120964	06-24-2004	MIKSZTA et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
AD		WO 01/189622	11-29-2001	MIKSZTA et al.		
AD		WO 01/139802	06-07-2001	CHAMBERS et al.		

Examiner Signature		Date Considered	11/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/679,036
Filing Date	10-02-2003
First Named Inventor	MIKSZTA et al.
Art Unit	1648
Examiner Name	MICHAEL M. MCGAW
Attorney Docket Number	P-6088

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
AD		International Search Report and Written Opinion of the International Search Authority for International Appl. No.: PCT/US2004/032354, mailed 04-May-2005.	

Examiner Signature		Date Considered	11/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

OIPE JC945
MAR 3 0 2005
PATENT & TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
11219-027-999 (500752-999026; P-6088)	10/679,036
APPLICANT: Mikszta et al.	
FILING DATE: October 2, 2003	GROUP: 3763

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AS	A01	2,619,962	12/1952	Rosenthal			
	A02	3,289,670	12/1966	Krug et al.			
	A03	3,556,080	01/1971	Hein			
	A04	3,814,097	06/1974	Ganderton, et al.			
	A05	3,964,482	06/1976	Gerstel et al.			
	A06	4,270,537	06/1981	Romaine			
	A07	4,270,548	06/1981	Brennen			
	A08	4,483,348	11/1984	Sher			
	A09	4,568,343	02/1986	Leeper et al.			
	A10	4,592,753	06/1986	Panoz			
	A11	4,597,764	07/1986	Black			
	A12	4,746,515	05/1988	Cheng et al.			
	A13	4,886,499	12/1989	Cirelli, et al.			
	A14	5,003,987	04/1991	Grinwald			
	A15	5,098,389	03/1992	Cappucci			
	A16	5,156,591	10/1992	Gross, et al.			
	A17	5,250,023	10/1993	Lee, et al.			
	A18	5,273,528	12/1993	Skeen et al.			
	A19	5,279,544	01/1994	Gross, et al.			
	A20	5,279,552	01/1994	Magnet			
	A21	5,380,337	01/1995	Romaine			
	A22	5,417,662	05/1995	Hjertman, et al.			
	A23	5,501,784	03/1996	Lessmollmann et al.			
	A24	5,527,288	06/1996	Gross, et al.			
	A25	5,582,591	12/1996	Cheikh			
	A26	5,591,139	01/1997	Lin, et al.			
	A27	5,611,806	03/1997	Jang			
	A28	5,658,515	08/1997	Lee et al.			
	A29	5,660,680	08/1997	Keller			
	A30	5,679,647	10/1997	Carson et al.			
	A31	5,801,057	09/1998	Smart, et al.			
	A32	5,820,622	10/1998	Gross, et al.			
	A33	5,848,990	12/1998	Cirelli, et al.			
	A34	5,848,991	12/1998	Gross et al.			
✓	A35	5,855,801	01/1999	Lin et al.			

A)	A36	5,876,582	03/1999	Frazier			
	A37	5,879,326	03/1999	Godshall, et al.			
	A38	5,885,211	03/1999	Eppstein et al.			
	A39	5,910,306	06/1999	Alving et al.			
	A40	5,919,364	07/1999	Lebouitz et al.			
	A41	5,928,207	07/1999	Pisano et al.			
	A42	5,931,794	08/1999	Pitesky			
	A43	5,957,895	09/1999	Sage, et al.			
	A44	5,958,589	09/1999	Glenn et al.			
	A45	5,970,998	10/1999	Talbot et al.			
	A46	5,980,898	11/1999	Glenn et al.			
	A47	5,983,136	11/1999	Kamen			
	A48	5,997,501	12/1999	Gross, et al.			
	A49	5,999,847	12/1999	Elstrom			
	A50	6,007,821	12/1999	Srivastava et al.			
	A51	6,015,599	01/2000	Keller et al.			
	A52	6,032,060	02/2000	Carim et al.			
	A53	6,050,988	04/2000	Zuck			
	A54	6,056,716	05/2000	D'Antonio, et al.			
	A55	6,065,864	05/2000	Evans et al.			
	A56	6,077,229	06/2000	Pitesky			
	A57	6,099,504	08/2000	Gross, et al.			
	A58	6,106,751	08/2000	Talbot et al.			
	A59	6,132,755	10/2000	Eicher et al.			
	A60	6,173,202	01/2001	Eppstein			
	A61	6,183,434	02/2001	Eppstein			
	A62	6,187,210	02/2001	Lebouitz et al.			
	A63	6,200,291	03/2001	Di Pietro			
	A64	6,230,051	05/2001	Cormier et al.			
	A65	6,241,739	06/2001	Waldron			
	A66	6,256,533	07/2001	Yuzhakov et al.			
	A67	6,299,900	10/2001	Reed et al.			
	A68	6,312,612	11/2001	Sherman et al.			
	A69	6,319,224	11/2001	Stout, et al.			
	A70	6,331,266	12/2001	Powell et al.			
	A71	6,334,856	01/2002	Allen et al.			
	A72	6,346,095	02/2002	Gross, et al.			
	A73	2002/0053756	05/2002	Powell et al.			
	A74	6,855,131	07/2002	Trautman et al.			
	A75	2002/0111600	08/2002	Cormier et al.			
	A76	6,454,755	09/2002	Godshall			
	A77	6,482,176	11/2002	Wich			
	A78	6,503,256	01/2003	Parkin et al.			
↓	A79	2003/0073609	04/2003	Pinkerton			

AJ	A80	6,562,014	05/2003	Lin et al.			
	A81	6,582,442	06/2003	Simon et al.			
	A82	2004/0028707	02/2004	Pinkerton			
	A83	2004/0073160	04/2004	Pinkerton			
	A84	2004/0170654	09/2004	Pinkerton			
	A85	2004/0175401	09/2004	Pinkerton			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AJ	B01	GB 2 125 280	03/1984	Great Britain				
	B02	EP 0 381 410	08/1990	Europe				
	B03	RU 172 4181	04/1992	Russian Federation				
	B04	WO 94/23777	10/1994	PCT				
	B05	DE 195 18 974	11/1995	Germany				
	B06	WO 96/07369	03/1996	PCT				
	B07	WO 96/17648	06/1996	PCT				
	B08	EP 0 429 842	08/1996	Europe				
	B09	EP 0 509 122	10/1996	Europe				
	B10	WO 96/37155	11/1996	PCT				
	B11	WO 96/37256	11/1996	PCT				
	B12	WO 97/03718	02/1997	PCT				
	B13	WO 97/11650	04/1997	PCT				
	B14	WO 97/21457	06/1997	PCT				
	B15	WO 97/48440	12/1997	PCT				
	B16	WO 97/48442	12/1997	PCT				
	B17	WO 99/00155	01/1999	PCT				
	B18	WO 99/20336	04/1999	Israel				
	B19	WO 99/43350	09/1999	PCT				
	B20	WO 99/64580	12/1999	PCT				
	B21	WO 00/09186	02/2000	PCT				
	B22	CA 2 349 431	05/2000	Canada				
	B23	EP 1 086 719	08/2000	Europe				
	B24	WO 00/67647	11/2000	PCT				
	B25	WO 00/74763	12/2000	PCT				
	B26	EP 1 086 718	03/2001	Europe				
	B27	EP 1 086 719	03/2001	Europe				
	B28	EP 1 088 642	04/2001	Europe				
	B29	EP 1 092 444	04/2001	Europe				
	B30	WO 01/39802	06/2001	PCT				
	B31	WO 02/11669	02/2002	PCT				
	B32	WO 02/083232	10/2002	PCT				
	B33	WO 03/002175	01/2003	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
AJ	C01	"Flu vaccine: skin injection method effective in younger people," *American Health Line: Research Notes* (2004 Nov. 4)
	C02	Agrawal et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in Mice," *Proc. Natl. Acad. Sci.* USA 88:7595-7599 (1991)
	C03	Autret et al., "Comparaison des concentrations plasmatiques et de la tolérance d'une dose unique de calcitonine humaine administree," *Therapie* 46:5-8 (1991)
	C04	Autret et al., "Comparison of pharmacokinetics and tolerance of calcitonine administered by intradermal or subcutaneous route," *Fundamental Clinical Pharmacology* 3(2):170-171 (1989)
	C05	Bader, "Influenza vaccine experience in Seattle," *Am. J. Public Health* 70(5):545 (1980)
	C06	Becker, "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans," *Virus Genes* 9(1):33-45 (1994)
	C07	Belshe et al., "Serum antibody responses after intradermal vaccination against influenza," *New England Journal of Medicine* 351(22):2286-2294 (2004)
	C08	Benoni et al., "Distribution of Ceftazidime in Ascitic Fluid, Antimicrobial Agents and Chemotherapy," 25(6):760-763 (1984)
	C09	Bickers et al., editors, "Glucocorticosteroids," *Clinical Pharmacology of Skin Disease* 57-90, Churchill Livingstone, Inc. (1984)
	C10	Bocci et al., "The lymphatic route. IV. pharmacokinetics of human recombinant interferon a2 and natural interferon beta administered intradermally in rabbits," *International Journal of Pharmaceutics* 32:103-110 (1986)
	C11	Branswell, "Vaccine stretching may be an option for future shortages, pandemics: studies," *Canadian Press News Wire* (2004 Nov. 3)
	C12	Bressolle et al., "A Weibull distribution model for intradermal administration of Ceftazidime," *Journal of Pharmaceutical Sciences* 82(11):1175-1178 (1993)
	C13	Bronaugh et al., "Methods for in vitro percutaneous absorption studies. II. animal models for human skin," *Toxicol Appl. Pharmacol.* 62(3):481-488 (1982)
	C14	Brooks et al., "Intradermal administration of bivalent and monovalent influenza vaccines." *Ann. Allergy. Aug.* 39(2):110-112 (1977)
	C15	Brown et al., "The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults." *J. Infect. Dis.* 136 Suppl:S466-71 (1977)
	C16	Burkoth et al., "Transdermal and transmucosal powdered drug delivery, critical Review™ in therapeutic drug carrier systems 16 (4):331-384 (1999)
	C17	Byrne et al., "Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice," *J. Invest. Dermatol.* 117(3):702-709 (2001)
	C18	Callen, "Intralesional corticosteriods," *Journal of the American Academy of Dermatology, University of Louisville School of Medicine* 149-151 (1981)
	C19	Corbo et al., "Transdermal controlled delivery of propranolol from a multilaminate adhesive device." *Pharm. Res.* 6(9):753-758 (1989)
	C20	Cossum et al., "Disposition of the c-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats," *The Journal of Pharmacology and Experimental Therapeutics* 267(3):1181-1190 (1993)
	C21	Cossum et al., "Pharmacokinetics of c-labeled phosphorothioate oligonucleotide, ISIS 2105 after administration to rats," *The Journal of Pharmacology and Experimental Therapeutics* 269(1):89-94 (1994)
	C22	Crooke et al., "A pharmacokinetic evaluation of c-labeled afovirsen sodium in patients with genital warts," *Clinical Pharmacology & Therapeutics* 56(6):641-646 December (1994)
	C23	Crowe, "Experimental comparison of intradermal and subcutaneous vaccination with influenza vaccine," *Am. J. Med. Technol.* 31(6):387-96 (1965)
	C24	Firooz, et al., "Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases," *Clinical and Experimental Dermatology* 20(5):363-370 (1995)
	C25	Fjerstad, "U. Minnesota professor uses alternative flu vaccine technique," *FSView & Florida Flambeau via U-Wire* (2004 Nov. 15)
	C26	Foy et al., "Efficacy of intradermally administered A2 Hong Kong vaccine," *JAMA* 213(1):130 (1970)
	C27	Glenn et al., "Advances in vaccine delivery: transcutaneous immunisation." *Exp. Opin. Invest. Drugs* 8(6):797-805 (1999)

AP	C28	Goodarzi et al., "Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice," *Biopharmaceutics & Drug Disposition* 13(3):221-227 (1992)
	C29	Gramzinski et al. "Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration," *Mol. Med.* 4(2):109-18 (1998)
	C30	Greenhalgh et al., "Epidermis: An Attractive Target Tissue for Gene Therapy," *Journal of Investigative Dermatology* 108(5):195-199 (1997)
	C31	Guirakhoo et al., "Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine," *J Virol.* 75(16):7290-7304 (2001)
	C32	Guirakhoo et al., "Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates," *J Virol.* 74(12):5477-5485 (2000)
	C33	Halperin et al., "A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature," *Am. J. Public Health.* 69(12):1247-1251 (1979)
	C34	Haynes et al., "Ultra-long-duration local anesthesia produced by injection of lecithin-coated methoxyflurane microdroplets," *Anesthesiology* 63(5):490-499 (1985)
	C35	Henry et al., "Microfabricated microneedles: a novel approach to transdermal drug delivery," *Journal of Pharmaceutical Sciences* 87(8):922-925 (1998)
	C36	Herbert et al., "Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease," *J. Infect. Dis.* 140(2):234-238 (1979)
	C37	Jakobson et al., "Variations in the blood concentration of 1,1,2-tricholoroethane by percutaneous absorption and other routes of administration in the guinea pig," *Acta Pharmacologizca et Toxicologica* 41(5):497-506 (1977)
	C38	Jarratt et al., "The effects of intradermal steroids on the pituitary-adrenal axis and the skin," *The Journal of Investigative Dermatology* 62(4):463-466 (1974)
	C39	Kaushik et al., "Transdermal Protein Delivery Using Microfabricated Microneedles," (1 page) (1999)
	C40	Kenney et al., "Dose sparing with intradermal injection of influenza vaccine," *New England Journal of Medicine* 351(22):2295-2301 (2004)
	C41	Kirkpatrick et al., "Local aesthetic efficacy of methoxyflurane microdroplets in man," *Anesthesiology* 67(3A):254 (1987)
	C42	Knox et al. "New research shows intradermal rather than intramuscular vaccine injection could stretch flu vaccine supplies," *National Public Radio: All Things Considered* (2004 Nov. 3)
	C43	Kohn, "Flu shot technique yields more doses, studies find; critics say injecting skin rather than muscle is too difficult for common use," *The Baltimore Sun: Telegraph* 3A (2004 Nov. 4)
	C44	Leroy et al., "Pharmacokinetics of ceftazidime in normal and uremic subjects," *Antimicrobal Agents and Chemotherapy* 25(5):638-642 (1984)
	C45	Li et al., "The feasibility of targeted selective gene therapy of the hair follicle," *Nature Medicine* 1(7):705-706 (1995)
	C46	Majeski et al., "Technique could stretch vaccine; changing the way shots are given means the current supply of flu vaccine could immunize 10 times as many people, two Minnesota physicians say" *Saint Paul Pioneer Press: Main 1A* (2004 Oct. 27)
	C47	Majeski, "Alternate flu shot less effective in elderly; doctors proposed method to stretch vaccine supply," *Saint Paul Pioneer Press: Main* 17A (2004 Nov. 4)
	C48	Márián et al., "Hypoglycemia activates compensatory mechanism of glucose metabolism of brain," *Acta Biologica Hungarica* 52(1):35-45 (2001)
	C49	Marovich et al., "Human dendritic cells as targets of dengue virus infection," *J Investig Dermatol Symp Proc.* 6(3):219-224 (2001)
	C50	McAllister et al., "Three-dimensional hollow microneedle and microtube arrays," *Solid-State Sensors and Actuators Transducers-Conference*; 1098-1103 (1999)
	C51	McAllister, et al., "Solid and Hollow Microneedles for transdermal protein delivery," *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater. Controlled Release Society.* 26:192-193 (1999)
	C52	McCluskie et al., "Skin Immunization Made Possible by Cholera Toxin," *Molecular Medicine* 5:287 1999. Nature, vol. 391, Feb. 26, 1998, p.851
	C53	McElroy et al., "Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine." *N. Engl. J. Med.* 281(19):1076 (1969)
	C54	McGugan et al., "Adrenal suppression from intradermal triamcinolone," *The Journal of Investigative Dermatology* 40:271-272 (1963)
	C55	Merriam-Webster's Collegiate Dictionary, 10th Edition, , Merriam-Webster, Inc., Springfield, MA, p. 306 (1998)

AD	C56	Montagne et al., "Intradermal influenza vaccination - can less be more?" *New England Journal of Medicine* 351(22):2330-2332 (2004)
	C57	Niculescu et al., "Efficacy of an adsorbed trivalent split influenza vaccine administered by intradermal route." *Arch. Roum. Path. Exp. Microbiol.* 40(1):67-70 (1981)
	C58	Payler, "Intradermal influenza vaccine using Portojet 1976," *Br. Med. J.* 2(6095):1152 (1977)
	C59	Payler et al. "Intradermal influenza vaccination," *Br. Med. J.* 2(921):727 (1974)
	C60	Raz et al., "Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses," *Proc. Natl. Acad. Sci., USA* 91:9519-9523 (1994)
	C61	Rindfleisch et al., "La Crosse finding could curtail flu vaccine shortages," *Wisconsin State Journal* D9 (2004 Nov. 14)
	C62	Scott et al., "Toxicity of Interferon," *British Medical Journal* 282:1345-1348 (1981)
	C63	Shute, "Second thoughts on the flu vaccine," *Science & Society; Public Health* 137(17):80
	C64	Smith, "Low-dose vaccine helps block flu, study says younger adults seen benefiting," *The Boston Globe: National/Foreign* A2 (2004 Nov. 4)
	C65	Supersaxo et al., "Recombinant human interferon Alpha-2a: delivery to lymphoid tissue by selected modes of application," *Pharmaceutical Research* 5(8):472-476 (1998)
	C66	Sutherest, "Treatment of pruritus vulvae by multiple intradermal injections of alcohol. a double-blind study," *British Journal of Obstetrics and Gynecology* 86:371-373 (1979)
	C67	Sveinsson, "Investigation on the influence of insulin and adrenalin in rabbits with alimentary fatty liver and muscles and on the content of fat and sugar in blood," 8:66-86 (1939)
	C68	Tang, "Vaccination onto Bare Skin," *Nature* 388:729 (1997)
	C69	Tauraso et al., "Effect of dosage and route of inoculation upon antigenicity of inactivated influenza virus vaccine (Hong Kong strain) in man," *Bull. World Health Organ.* 41(3):507-16 (1969)
	C70	Taweechaisupapong et al., "In vivo and in vitro studies on the morphological change in the monkey epidermal Langerhans cells following exposure to dengue 2 (16681) virus," *Southeast Asian J Trop Med Public Health* 27(4):664-672 (1996)
	C71	Taweechaisupapong et al., "Langerhans cell density and serological changes following intradermal immunisation of mice with dengue 2 virus," *J Med Microbiol.* 45(2):138-145 (1996)
	C72	The American Heritage College Dictionary, 3rd Edition; Houghton Mifflin Company, Boston, New York, p. 368 (2000)
	C73	The Merck Manual of Diagnosis and Therapy, 17th Edition, Beers & Berkow, ed., Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ, pp. 2555-2571 (1999)
	C74	Tuberculin, Old Mono-Vacc Test (O.T.), product information, www.us.aventispasteur.com
	C75	Van De Graff, et al., *Concepts of Human Anatomy and Physiology*, pp. 197-1999 USA Wm. C. Brown Publishers (1986)
	C76	Ward et al., "Puritus vulvae: treatment by multiple intradermal alcohol injections," *British Journal of Dermatology* 93(2):201-204 (1975)
	C77	Wu et al., "Human skin Langerhans cells are targets of dengue virus infection," *Nat Med.* 6(7):816-820 (2000)
	C78	Wu et al., "Pharmacokinetics of methoxyflurane after its intra-dermal injection as lecithin-coated microdroplets," *Journal of Controlled Release* 9:1-12 (1989)
	C79	Yokohama et al., "DNA Immunization: Effects of Vehicle and Route of Administration on the Induction of Protective Antiviral Immunity," *FEMS Immunology and Medical Mircobiology* 14:221-230 (1996)
	C80	Zaynoun et al., "The effect of intracutaneous glucocorticoids on plasma cortisol levels," *British Journal of Dermatology* 88(2):151-156 (1973)

EXAMINER	**DATE CONSIDERED** 11/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.